Incretin Atlas › Trials › EECOH-1
EECOH-1
Ecnoglutide · t2d
Design
- Molecule(s)
- Ecnoglutide
- Population
- t2d
- Phase
- 3
- Participants
- 211
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.6 mg | t2d china | 24 | 211 | — | —−4.5 % vs −2.0 % estimand not specified | −2.0 vs −0.9 | 1.4 vs 1.4 | 4.3 vs 2.8 | 7.2 vs 9.9 | — | 2.9 vs 5.6 | — | press release |
| ecnoglutide 1.2 mg | t2d china | 24 | 71 | — | −4.7 % vs −2.0 % Δ −2.7 pp | −2.4 vs −0.9 | 1.4 vs 1.4 | 5.6 vs 2.8 | 12.7 vs 9.9 | — | 4.2 vs 5.6 | −5.2 vs −2.1 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (13)
- 0.6 mg · hba1c · press release
HbA1c change from baseline | -0.87 % | -1.96% ( P =0.0003) | -2.43% ( P< 0.0001)
- 0.6 mg · weight_unsp · press release
Percent body weight change from baseline | -2.02 % | -4.51% ( P =0.0002) | -4.74% ( P< 0.0001)
- 0.6 mg · ae_dc · press release
A total of three subjects, one (1.4%) from each cohort, discontinued the study due to adverse events.
- 0.6 mg · disc_any · Results, para 1
and safety set, and 9 (4%) of them discontinued treatment prematurely in the double-blind period, including 3 from the 0.6 mg ecnoglutide group, 4 from the 1.2 mg ecnoglutide group, and 2 from the pooled placebo group (r
- 0.6 mg · nausea · Table 3 (double-blind period, safety set; columns: 1.2 mg N=
Nausea 9 (12.7) 5 (7.2) 7 (9.9)
- 0.6 mg · sae · Table 3 (double-blind period, safety set; columns: 1.2 mg N=
Serious TEAEs 3 (4.2) 2 (2.9) 4 (5.6)
- ecnoglutide 1.2 mg · weight_tp · Results, Secondary outcomes; Table 2
−4.74% (−5.65 to −3.82) with 1.2 mg ecnoglutide
- ecnoglutide 1.2 mg · ae_dc · Results, Safety outcomes; Table 3
TEAEs led to premature treatment discontinuation in 1 (1.4%) participant in each treatment group (Table 3).
- ecnoglutide 1.2 mg · disc_any · Results, Study participants (denominator 71 from Table 3/Fig
including 3 from the 0.6 mg ecnoglutide group, 4 from the 1.2 mg ecnoglutide group, and 2 from the pooled placebo group
- ecnoglutide 1.2 mg · nausea · Table 3
Nausea 9 (12.7) 5 (7.2) 7 (9.9)
- ecnoglutide 1.2 mg · sae · Results, Safety outcomes; Table 3
Serious TEAEs were reported in 2.9% (2/69) of the 0.6 mg ecnoglutide group, 4.2% (3/71) of the 1.2 mg ecnoglutide group, and 5.6% (4/71) of the placebo group.
- ecnoglutide 1.2 mg · hba1c · Results, Primary outcome; Table 2
−2.43% (−2.65 to −2.20) with 1.2 mg ecnoglutide
- ecnoglutide 1.2 mg · sbp · Results, Safety outcomes
a mean of 5.2 mmHg with 1.2 mg ecnoglutide
Primary sources
- Sciwind. Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003) in Adult Patients with Type 2 Diabetes in China [press release]. 2024-01-02. Available from: https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-positive-topline-results-from-phase-3-clinical-trial-of-ecnoglutide-xw003-a-long-acting-camp-signaling-biased-glp-1-analog-in-adult-patients-with-type-2-diabetes-in-china-302023591.html
- Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026;17(1):1420. PMID: 41501026.
How to cite this page
Medical Adviser's Group. Incretin Atlas: EECOH-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/eecoh-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.